Re-examining the Optimal Use of Neuromodulators and the Changing Landscape: A Consensus Panel Update
1 CME CreditSince initial US Food and Drug Administration approval of botulinum toxin type A (BoNT-A) for aesthetic use in 2002, clinical evidence and experience with BoNT-A and understanding of…
Read More















